172 related articles for article (PubMed ID: 38569945)
21. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
[TBL] [Abstract][Full Text] [Related]
22. [Research on the natural history of non-alcoholic fatty liver disease should be taken seriously].
Zhao ZH; Liu XL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):81-84. PubMed ID: 28297791
[TBL] [Abstract][Full Text] [Related]
23. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
Kuchay MS; Misra A
Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
[TBL] [Abstract][Full Text] [Related]
24. The epidemiology of nonalcoholic fatty liver disease in adults.
Clark JM
J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
[TBL] [Abstract][Full Text] [Related]
25. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
26. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
Anstee QM; Targher G; Day CP
Nat Rev Gastroenterol Hepatol; 2013 Jun; 10(6):330-44. PubMed ID: 23507799
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.
de Vries M; El-Morabit F; van Erpecum KJ; Westerink J; Bac ST; Kaasjager HAHK; de Valk HW
Eur J Intern Med; 2022 Jun; 100():77-82. PubMed ID: 35387749
[TBL] [Abstract][Full Text] [Related]
28. [Prevalence and harm of nonalcoholic fatty liver disease].
Shao YL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917
[TBL] [Abstract][Full Text] [Related]
29. Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis.
Younossi ZM; Henry L
Endocr Pract; 2022 Feb; 28(2):204-213. PubMed ID: 34952219
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
31. Steatosis and NASH in type 2 diabetes.
Hu M; Phan F; Bourron O; Ferré P; Foufelle F
Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
[TBL] [Abstract][Full Text] [Related]
32. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Le MH; Le DM; Baez TC; Dang H; Nguyen VH; Lee K; Stave CD; Ito T; Wu Y; Yeo YH; Ji F; Cheung R; Nguyen MH
Clin Mol Hepatol; 2024 Apr; 30(2):235-246. PubMed ID: 38281814
[TBL] [Abstract][Full Text] [Related]
33. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
Nasr P; Blomdahl J; Kechagias S; Ekstedt M
Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
[TBL] [Abstract][Full Text] [Related]
34. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
Teng PC; Huang DQ; Lin TY; Noureddin M; Yang JD
Gut Liver; 2023 Jan; 17(1):24-33. PubMed ID: 36530125
[TBL] [Abstract][Full Text] [Related]
35. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
37. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
38. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
[TBL] [Abstract][Full Text] [Related]
40. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
